Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne

Study subjects will be assigned to one of two treatment groups. Both treatment groups will receive treatment in the center of the forehead/temples, medial cheeks, and chin regions using the 1.5mm and 1.0mm transducers.

• For Group A, both the 1.5mm and 1.0mm transducers will be used at 0.25J energy setting and 0.20J energy setting, respectively.
• For Group B, both the 1.5mm and 1.0mm transducers will be used at 0.18J energy setting and 0.15J energy setting, respectively.

Subjects will receive 3 Ultherapy treatments administered 2 weeks apart. Subjects will be required to return for follow-up assessments at 14, 30, 60, 90 and 180 days following the third Ultherapy treatment. Pre- and post-treatment photos will be taken. In addition, pre- and post-treatment lesion counts and sebum measurements will be obtained.

Inclusion criteria

• Male or female, aged 18 years and older.
• Subject in good health.
• Presence of clinically-evident facial acne of moderate to severe severity with at least 20 inflammatory lesions and 20-100 noninflammatory lesions.

Exclusion criteria

• Presence of >2 nodular lesions in the areas to be treated.
• Presence of any cysts in the areas to be treated.
• Presence of an active systemic or local skin disease that may affect wound healing.
• Use of alcohol-based topical solutions or "exfoliating" agents within 1 week prior to study participation.
• History of frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.
• History of keloid scar formation.
• Significant scarring in areas to be treated.
• Significant open facial wounds or lesions.
• Presence of a metal stent or implant in the facial area to be treated.